对急性高危对乙酰氨基酚(对乙酰氨基酚)摄入进行大剂量乙酰半胱氨酸评估。

IF 3 3区 医学 Q2 TOXICOLOGY
Clinical Toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI:10.1080/15563650.2024.2377268
Michael J Moss, Brynne Hinchman, Joseph E Lambson, Julie W Scott, Paul Hinckley, Sawyer J Wylie, Alyrene Dorey
{"title":"对急性高危对乙酰氨基酚(对乙酰氨基酚)摄入进行大剂量乙酰半胱氨酸评估。","authors":"Michael J Moss, Brynne Hinchman, Joseph E Lambson, Julie W Scott, Paul Hinckley, Sawyer J Wylie, Alyrene Dorey","doi":"10.1080/15563650.2024.2377268","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepatotoxicity is reported despite early treatment when paracetamol concentrations exceed 300 mg/L (1,985 μmol/L) at 4 h. Prior studies evaluating high-dose acetylcysteine to treat high-risk ingestions have shown mixed results. We compared outcomes in patients with high-risk ingestions receiving standard or high-dose acetylcysteine.</p><p><strong>Methods: </strong>Records from a single poison center were reviewed from 1 January 2017 to 31 December 2022. We included cases of acute paracetamol ingestion treated with intravenous acetylcysteine with an initial paracetamol concentration above the \"300 mg/L\" (1,985 μmol/L) line on the Rumack-Matthew nomogram. We compared standard and high-dose acetylcysteine groups by odds ratios and multivariable logistic regression. We defined hepatotoxicity as aminotransferase activity >1,000 U/L.</p><p><strong>Results: </strong>We included 190 cases. Fifty-six percent received standard-dose acetylcysteine while 44% received high-dose acetylcysteine. Treatment within 8 h yielded no difference in hepatotoxicity between groups (odds ratio 1.67, 95% CI 0.067-42.3). Among patients treated after 8 h, hepatoxicity was more common in the high-dose group (odds ratio 3.39, 95% CI 1.25-9.2) though odds of liver failure were similar (odds ratio 2.78, 95% CI 0.89-8.69). Eighty-eight percent of patients with hepatotoxicity had elevated aminotransferase activity at presentation. No patient died or received a liver transplant.</p><p><strong>Discussion: </strong>Rates of hepatotoxicity were low in patients treated within 8 h regardless of acetylcysteine dose. Unexpectedly, high-dose acetylcysteine treatment was associated with an increased odds of hepatoxicity in those treated after 8 h, but most had abnormal aminotransferase activities at presentation and there was no difference in rates of liver failure. Limitations include the use of retrospective, voluntarily reported poison center data.</p><p><strong>Conclusions: </strong>Prompt treatment with acetylcysteine, regardless of dose, prevented hepatotoxicity in high-risk paracetamol ingestion.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"519-525"},"PeriodicalIF":3.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of high-dose acetylcysteine in acute high-risk paracetamol (acetaminophen) ingestion.\",\"authors\":\"Michael J Moss, Brynne Hinchman, Joseph E Lambson, Julie W Scott, Paul Hinckley, Sawyer J Wylie, Alyrene Dorey\",\"doi\":\"10.1080/15563650.2024.2377268\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepatotoxicity is reported despite early treatment when paracetamol concentrations exceed 300 mg/L (1,985 μmol/L) at 4 h. Prior studies evaluating high-dose acetylcysteine to treat high-risk ingestions have shown mixed results. We compared outcomes in patients with high-risk ingestions receiving standard or high-dose acetylcysteine.</p><p><strong>Methods: </strong>Records from a single poison center were reviewed from 1 January 2017 to 31 December 2022. We included cases of acute paracetamol ingestion treated with intravenous acetylcysteine with an initial paracetamol concentration above the \\\"300 mg/L\\\" (1,985 μmol/L) line on the Rumack-Matthew nomogram. We compared standard and high-dose acetylcysteine groups by odds ratios and multivariable logistic regression. We defined hepatotoxicity as aminotransferase activity >1,000 U/L.</p><p><strong>Results: </strong>We included 190 cases. Fifty-six percent received standard-dose acetylcysteine while 44% received high-dose acetylcysteine. Treatment within 8 h yielded no difference in hepatotoxicity between groups (odds ratio 1.67, 95% CI 0.067-42.3). Among patients treated after 8 h, hepatoxicity was more common in the high-dose group (odds ratio 3.39, 95% CI 1.25-9.2) though odds of liver failure were similar (odds ratio 2.78, 95% CI 0.89-8.69). Eighty-eight percent of patients with hepatotoxicity had elevated aminotransferase activity at presentation. No patient died or received a liver transplant.</p><p><strong>Discussion: </strong>Rates of hepatotoxicity were low in patients treated within 8 h regardless of acetylcysteine dose. Unexpectedly, high-dose acetylcysteine treatment was associated with an increased odds of hepatoxicity in those treated after 8 h, but most had abnormal aminotransferase activities at presentation and there was no difference in rates of liver failure. Limitations include the use of retrospective, voluntarily reported poison center data.</p><p><strong>Conclusions: </strong>Prompt treatment with acetylcysteine, regardless of dose, prevented hepatotoxicity in high-risk paracetamol ingestion.</p>\",\"PeriodicalId\":10430,\"journal\":{\"name\":\"Clinical Toxicology\",\"volume\":\" \",\"pages\":\"519-525\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15563650.2024.2377268\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"TOXICOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15563650.2024.2377268","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:及时使用标准剂量(300 毫克/千克,21 小时内分次服用)的乙酰半胱氨酸治疗对预防扑热息痛(对乙酰氨基酚)过量后的肝毒性几乎普遍有效。然而,当扑热息痛在 4 小时内浓度超过 300 毫克/升(1,985 μmol/L)时,尽管及早治疗,仍会出现肝中毒。我们比较了接受标准剂量或高剂量乙酰半胱氨酸治疗的高危摄入患者的疗效:我们回顾了一家毒物中心从 2017 年 1 月 1 日至 2022 年 12 月 31 日的记录。我们纳入了接受乙酰半胱氨酸静脉注射治疗的急性扑热息痛摄入病例,其初始扑热息痛浓度高于鲁马克-马修提名图上的 "300 毫克/升"(1,985 μmol/L)线。我们通过几率比和多变量逻辑回归对标准剂量组和高剂量乙酰半胱氨酸组进行了比较。我们将转氨酶活性>1,000 U/L定义为肝毒性:我们纳入了 190 个病例。56%的患者接受了标准剂量的乙酰半胱氨酸治疗,44%的患者接受了高剂量的乙酰半胱氨酸治疗。在 8 小时内接受治疗的患者,其肝脏毒性在组间无差异(几率比 1.67,95% CI 0.067-42.3)。在 8 小时后接受治疗的患者中,虽然肝功能衰竭的几率相似(几率比 2.78,95% CI 0.89-8.69),但肝中毒在大剂量组更为常见(几率比 3.39,95% CI 1.25-9.2)。88%的肝毒性患者在发病时转氨酶活性升高。没有患者死亡或接受肝移植:讨论:无论乙酰半胱氨酸的剂量如何,在8小时内接受治疗的患者肝毒性发生率较低。出乎意料的是,大剂量乙酰半胱氨酸治疗增加了8小时后接受治疗的患者出现肝中毒的几率,但大多数患者在就诊时转氨酶活性异常,肝功能衰竭的发生率也没有差异。结论:乙酰半胱氨酸的及时治疗与肝中毒的发生率无关:结论:及时使用乙酰半胱氨酸治疗(无论剂量大小)可预防高风险扑热息痛摄入者的肝中毒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessment of high-dose acetylcysteine in acute high-risk paracetamol (acetaminophen) ingestion.

Background: Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepatotoxicity is reported despite early treatment when paracetamol concentrations exceed 300 mg/L (1,985 μmol/L) at 4 h. Prior studies evaluating high-dose acetylcysteine to treat high-risk ingestions have shown mixed results. We compared outcomes in patients with high-risk ingestions receiving standard or high-dose acetylcysteine.

Methods: Records from a single poison center were reviewed from 1 January 2017 to 31 December 2022. We included cases of acute paracetamol ingestion treated with intravenous acetylcysteine with an initial paracetamol concentration above the "300 mg/L" (1,985 μmol/L) line on the Rumack-Matthew nomogram. We compared standard and high-dose acetylcysteine groups by odds ratios and multivariable logistic regression. We defined hepatotoxicity as aminotransferase activity >1,000 U/L.

Results: We included 190 cases. Fifty-six percent received standard-dose acetylcysteine while 44% received high-dose acetylcysteine. Treatment within 8 h yielded no difference in hepatotoxicity between groups (odds ratio 1.67, 95% CI 0.067-42.3). Among patients treated after 8 h, hepatoxicity was more common in the high-dose group (odds ratio 3.39, 95% CI 1.25-9.2) though odds of liver failure were similar (odds ratio 2.78, 95% CI 0.89-8.69). Eighty-eight percent of patients with hepatotoxicity had elevated aminotransferase activity at presentation. No patient died or received a liver transplant.

Discussion: Rates of hepatotoxicity were low in patients treated within 8 h regardless of acetylcysteine dose. Unexpectedly, high-dose acetylcysteine treatment was associated with an increased odds of hepatoxicity in those treated after 8 h, but most had abnormal aminotransferase activities at presentation and there was no difference in rates of liver failure. Limitations include the use of retrospective, voluntarily reported poison center data.

Conclusions: Prompt treatment with acetylcysteine, regardless of dose, prevented hepatotoxicity in high-risk paracetamol ingestion.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Toxicology
Clinical Toxicology 医学-毒理学
CiteScore
5.70
自引率
12.10%
发文量
148
审稿时长
4-8 weeks
期刊介绍: clinical Toxicology publishes peer-reviewed scientific research and clinical advances in clinical toxicology. The journal reflects the professional concerns and best scientific judgment of its sponsors, the American Academy of Clinical Toxicology, the European Association of Poisons Centres and Clinical Toxicologists, the American Association of Poison Control Centers and the Asia Pacific Association of Medical Toxicology and, as such, is the leading international journal in the specialty.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信